Skip to main content
SpringerLink
Log in

Farnesyltransferase Inhibitors

Potential Role in the Treatment of Cancer

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

New targets for drug discovery have been identified rapidly as a result of the many recent and rapid advances in the understanding of signal transduction pathways that contribute to oncogenesis. In particular, oncogenic Ras proteins have been seen as an important target for novel anti-cancer drugs. Since the decade-old identification and cloning of farnesyltransferase (FTase), a critical enzyme that post-translationally modifies Ras and other farnesylated proteins, FTase inhibitors (FTIs) have been under intense investigation designed to bring them to clinical practice for cancer therapy.

FTIs can inhibit the growth of tumour cells in culture and in animal models, and are now in clinical trials. Interestingly, their mechanism of action is not as simple as originally envisioned, and Ras is probably not the most important farnesylated protein whose modification is inhibited as a result of FTI treatment. Although K-Ras can escape inhibition of processing by FTIs, tumours with oncogenically mutated K-Ras proteins can still be inhibited by FTI treatment. Indeed, Ras mutation status does not correlate with FTI sensitivity or resistance. Instead, it now appears likely that inhibition of the processing of other farnesylated proteins such as RhoB and the centromere-binding proteins CENP-E and CENP-F can explain the ability of FTIs to cause cell cycle arrest and apoptosis in preclinical studies, and even to cause regression in animal tumour models.

Preclinical studies suggest the likelihood that FTIs will be useful in combination therapies with conventional treatment modalities including cytotoxics (especially paclitaxel) and radiation. Phase I combination trials are underway, and early phase II/III trials using FTIs as monotherapy are open for patients with a wide variety of cancers. Early preclinical results also suggest the possibility of using FTIs as chemopreventive agents.

Studies to be completed over the next 2 or 3 years should define the appropriate patient populations, administration and scheduling necessary to optimise the use of these novel anticancer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don’t fall far from the tree. Curr Opin Cell Biol 2000; 12: 157–65

    Article  PubMed  CAS  Google Scholar 

  2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9

    PubMed  CAS  Google Scholar 

  3. Shirasawa S, Furuse M, Yokoyama N, et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260: 85–8

    Article  PubMed  CAS  Google Scholar 

  4. Plattner R, Anderson MJ, Sato KY, et al. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci U S A 1996; 93: 6665–70

    Article  PubMed  CAS  Google Scholar 

  5. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1997; 1333:F51–F71

    PubMed  CAS  Google Scholar 

  6. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221–5

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–30

    Article  PubMed  CAS  Google Scholar 

  8. Cox AD, Toussaint LG III, Fiordalisi JJ, et al. Farnesyltransferase and geranylgeranyltransferase inhibitors: the saga continues. In: Sebti SM, Hamilton AD, editors. Farnesyltransferase inhibitors in cancer therapy. Totowa (NJ): Humana Press, 2000: 255–73

    Chapter  Google Scholar 

  9. Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim Biophys Acta 1999; 1423: C19–C30

    PubMed  CAS  Google Scholar 

  10. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631–52

    PubMed  CAS  Google Scholar 

  11. Gibbs JB. Farnesyltransferase inhibitors. In: Tamanoi F, Sigman D, editors. Protein lipidation. The Enzymes 1. Vol XXI. San Diego (CA): Academic Press, 2000: 81–103

    Google Scholar 

  12. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 1:792–7

    Article  PubMed  CAS  Google Scholar 

  13. Liu M, Bryant MS, Chen J, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998; 58: 4947–56

    PubMed  CAS  Google Scholar 

  14. Rowell CA, Kowalczyk JJ, Lewis MD, et al. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997; 272: 14093–7

    Article  PubMed  CAS  Google Scholar 

  15. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459–64

    Article  PubMed  CAS  Google Scholar 

  16. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302–9

    PubMed  CAS  Google Scholar 

  17. Nagasu T, Yoshimatsu K, Rowell C, et al. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B 956. Cancer Res 1995; 55: 5310–14

    PubMed  CAS  Google Scholar 

  18. Miquel K, Pradines A, Sun J, et al. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 1997; 57: 1846–50

    PubMed  CAS  Google Scholar 

  19. Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 1997; 57: 708–13

    PubMed  CAS  Google Scholar 

  20. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A 1998; 95: 15356–61

    Article  PubMed  CAS  Google Scholar 

  21. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999; 19: 1831–40

    PubMed  CAS  Google Scholar 

  22. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139–48

    Article  PubMed  Google Scholar 

  23. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43: S61–S8

    Article  PubMed  CAS  Google Scholar 

  24. Manne V, Ricca C, Gullo-Brown J, et al. BMS-214662, a highly potent apoptotic farnesyltransferase inhibitor [abstract no. 1399]. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research; 2000 Apr 1–5: San Francisco (CA). Philadelphia (PA): the American Association for Cancer Research, 2000

    Google Scholar 

  25. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998; 17: 1439–45

    Article  PubMed  CAS  Google Scholar 

  26. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000; 275: 30451–7

    Article  PubMed  CAS  Google Scholar 

  27. Chen Z, Sun J, Pradines A, et al. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000; 275: 17974–8

    Article  PubMed  CAS  Google Scholar 

  28. Liu A, Du W, Liu JP, et al. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000; 20: 6105–13

    Article  PubMed  CAS  Google Scholar 

  29. Barrington RE, Subler MA, Rands E, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998; 18: 85–92

    PubMed  CAS  Google Scholar 

  30. Mangues R, Corral T, Kohl NE, et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 1998; 58: 1253–9

    PubMed  CAS  Google Scholar 

  31. Omer CA, Chen Z, Diehl RE, et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: protein transferase inhibitor. Cancer Res 2000; 60: 2680–8

    PubMed  CAS  Google Scholar 

  32. Maity A, Kao GD, Muschel RJ, et al. Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys 1997; 37: 639–53

    Article  PubMed  CAS  Google Scholar 

  33. Bernhard EJ, Kao G, Cox AD, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 1996; 56: 1727–30

    PubMed  CAS  Google Scholar 

  34. Bernhard EJ, McKenna WG, Hamilton AD, et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 1998; 58: 1754–61

    PubMed  CAS  Google Scholar 

  35. Sun J, Qian Y, Hamilton AD, et al. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998; 16: 1467–73

    Article  PubMed  CAS  Google Scholar 

  36. Cohen-Jonathan E, Toulas C, Ader I, et al. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res 1999; 152: 404–11

    Article  PubMed  CAS  Google Scholar 

  37. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A 1998; 95: 1369–74

    Article  PubMed  CAS  Google Scholar 

  38. Sepp-Lorenzino L, Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 1998; 273: 20243–51

    Article  PubMed  CAS  Google Scholar 

  39. Suzuki N, Del Villar K, Tamanoi F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci U S A 1998; 95: 10499–504

    Article  PubMed  CAS  Google Scholar 

  40. Sun J, Blaskovich MA, Knowles D, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res 1999; 59: 4919–26

    PubMed  CAS  Google Scholar 

  41. Peeters M, Van Cutsem E, Marse H, et al. Phase-I combination trial of the farnesyltransferase inhibitor (FTI) RI 15777 with a 5FU/LV regimen in advanced colorectal (CR) or pancreatic (PC) cancer [abstract no. 859]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18: Atlanta (GA)

  42. Hurwitz HI, Colvin OM, Petros WP, et al. Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule, [abstract no. 599]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18: Atlanta (GA)

  43. Britten CD, Rowinsky E, Yao S-L, et al. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers [abstract no. 597]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18: Atlanta (GA)

  44. Awada A, Eskens F, Piccart M, et al. A clinical, pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH) an oral inhibitor of the enzyme farnesyl transferase given once daily in patients with solid tumors [abstract no. 20]. Proceedings of the First International Conference of the American Association for Cancer Research — National Cancer Institutes — European Organization for Research and Treatment of Cancer; 1999 Nov 16–19; Washington, DC; 1: 5

  45. Khuri F, Glisson BS, Meyers ML, et al. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety [abstract no 799]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23: New Orleans (LA)

  46. Hurwitz HI, Amado R, Prager D, et al. Phase I pharmacokinetic trial of the farnesyltransferase inhibitor SCH66336 plus gemcitabine in advanced cancers [abstract no 717]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23: New Orleans (LA)

  47. Johnston SR, Ellis PA, Houston S, et al. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer [abstract no 318]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23: New Orleans (LA)

  48. Lancet JE, Rosenblatt JD, Liesveld JL, et al. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: preliminary results of a phase I trial [abstract no 5B]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23: New Orleans (LA)

  49. Hahn SM, Kiel K, Morrison BW, et al. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 in combination with radiotherapy [abstract no 906]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23: New Orleans (LA)

  50. Sonnischen D, Damle B, Manning J, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors [abstract no 691]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23: New Orleans (LA)

  51. Adjei AA, Davis JN, Erlichman C, et al. Farnesyltransferase inhibitors: use of surrogate markers. Proceedings of the First International Conference of the American Association for Cancer Research — National Cancer Institutes — European Organization for Research and Treatment of Cancer; 1999 Nov 16–19; Washington, DC; 1: 145

  52. Elson CE. Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease. J Nutr 1995; 125: 1666S–72S

    PubMed  CAS  Google Scholar 

  53. Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999; 129: 775S–8S

    PubMed  CAS  Google Scholar 

  54. Crowell PL, Siar Ayoubi A, Burke YD. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Adv Exp Med Biol 1996; 401: 131–6

    Article  PubMed  CAS  Google Scholar 

  55. Stayrook KR, McKinzie JH, Burke YD, et al. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 1997; 18: 1655–8

    Article  PubMed  CAS  Google Scholar 

  56. Bol DK, Dell J, Ho CP, et al. A comparison of the therapeutic and preventive efficacy of a novel Ras farnesyltransferase inhibitor in endogenous mouse carcinogenesis models [abstract]. Proceedings of the 91 st Annual Meeting of the American Association for Cancer Research; 2000 Apr 1–5: San Francisco (CA). Philadelphia (PA): the American Association for Cancer Research, 2000

    Google Scholar 

  57. Prendergast GC, Davide JP, Lebowitz PF, et al. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res 1996; 56: 2626–32

    PubMed  CAS  Google Scholar 

  58. Yokoyama K, Trobridge P, Buckner FS, et al. The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol Biochem Parasitai 1998; 94: 87–97

    Article  CAS  Google Scholar 

  59. Chakrabarti D, Azam T, DelVecchio C, et al. Protein prenyl transferase activities of Plasmodium falciparum. Mol Biochem Parasitai 1998; 94: 175–84

    Article  CAS  Google Scholar 

  60. Sonoda K, Sakamoto T, Yoshikawa H, et al. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization. Invest Ophthalmol Vis Sci 1998; 39: 2245–51

    PubMed  CAS  Google Scholar 

  61. Randall SK, Marshall MS, Crowell DN. Protein isoprenylation in suspension-cultured tobacco cells. Plant Cell 1993; 5: 433–42

    PubMed  CAS  Google Scholar 

  62. Biermann BJ, Morehead TA, Tate SE, et al. Novel isoprenylated proteins identified by an expression library screen. J Biol Chem 1994; 269: 25251–4

    PubMed  CAS  Google Scholar 

  63. Parmryd I, Andersson B, Dallner G. Protein prenylation in spinach chloroplasts. Proc Natl Acad Sci U S A 1999; 96: l0074–9

    Article  Google Scholar 

  64. Pei ZM, Ghassemian M, Kwak CM, et al. Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. Science 1998; 282: 287–90

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Helpful discussions with members of the laboratory and with our collaborators Channing Der, Saïd Sebti and Andy Hamilton are gratefully acknowledged. Our research is supported by NIH grants (CA67771 and CA 76092).

Author information

Authors and Affiliations

  1. Departments of Radiation Oncology and Pharmacology, Lineberger Cancer Center, Curriculum in Genetics and Molecular Biology, School of Medicine, CB #7512, University of North Carolina at Chapel Hill, 101 Manning Drive, 1050 NCCCC, Chapel Hill, North Carolina, 27599-7512, USA

    Adrienne D. Cox

Authors
  1. Adrienne D. Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrienne D. Cox.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cox, A.D. Farnesyltransferase Inhibitors. Drugs 61, 723–732 (2001). https://doi.org/10.2165/00003495-200161060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161060-00002

Keywords

Search

Navigation